Sunshine Noroo announced that the company, in collaboration with Yimiao Shenzhou and its wholly-owned subsidiary Again Miao Biotech, received the "Drug Clinical Trial Approval Letter" issued by the National Medical Products Administration for the research and development project "ZM001 Injection", and the clinical trial application has been approved. ZM001 is intended for the treatment of systemic lupus erythematosus (SLE). Sunshine Noroo is the exclusive partner for the indication of SLE for ZM001. However, it is important to note that drug development cycles are long, with many approval steps and are susceptible to uncertainty factors, so investors should make decisions carefully and be cautious about investment risks.